TGTX Tg Therapeutics Inc

Price (delayed)

$36.7

Market cap

$5.19B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.61

Enterprise value

$4.76B

Highlights
The company's net income has shrunk by 69% YoY and by 14% QoQ
Tg Therapeutics's EPS has decreased by 31% YoY and by 8% QoQ

Key stats

What are the main financial stats of TGTX
Market
Shares outstanding
141.47M
Market cap
$5.19B
Enterprise value
$4.76B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
11.59
Price to sales (P/S)
5,337.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5,247.62
Earnings
Revenue
$907,000
EBIT
-$311.87M
EBITDA
-$311.68M
Free cash flow
-$234.1M
Per share
EPS
-$2.61
Free cash flow per share
-$1.77
Book value per share
$3.17
Revenue per share
$0.01
TBVPS
$4.15
Balance sheet
Total assets
$548.7M
Total liabilities
$103.41M
Debt
$40.48M
Equity
$445.29M
Working capital
$442.52M
Liquidity
Debt to equity
0.09
Current ratio
5.78
Quick ratio
5.69
Net debt/EBITDA
1.39
Margins
EBITDA margin
-34,363.7%
Gross margin
84.7%
Net margin
-35,159.1%
Operating margin
-34,459.9%
Efficiency
Return on assets
-73.2%
Return on equity
-95.9%
Return on invested capital
-4,251.6%
Return on capital employed
-68.4%
Return on sales
-34,384.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TGTX stock price

How has the Tg Therapeutics stock price performed over time
Intraday
-1.9%
1 week
-1.61%
1 month
7.12%
1 year
101.76%
YTD
-29.45%
QTD
-23.86%

Financial performance

How have Tg Therapeutics's revenue and profit performed over time
Revenue
$907,000
Gross profit
$768,000
Operating income
-$312.55M
Net income
-$318.89M
Gross margin
84.7%
Net margin
-35,159.1%
TGTX's net margin has soared by 81% QoQ and by 72% YoY
Tg Therapeutics's operating margin has surged by 81% QoQ and by 72% YoY
The operating income has plunged by 69% YoY and by 14% from the previous quarter
The company's net income has shrunk by 69% YoY and by 14% QoQ

Growth

What is Tg Therapeutics's growth rate over time

Valuation

What is Tg Therapeutics stock price valuation
P/E
N/A
P/B
11.59
P/S
5,337.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5,247.62
Tg Therapeutics's EPS has decreased by 31% YoY and by 8% QoQ
The P/B is 25% below the 5-year quarterly average of 15.5 and 22% below the last 4 quarters average of 14.9
The equity has declined by 14% since the previous quarter
The P/S is 74% below the last 4 quarters average of 20465.3 and 28% below the 5-year quarterly average of 7422.7

Efficiency

How efficient is Tg Therapeutics business performance
The company's return on equity has surged by 97% YoY and by 24% QoQ
Tg Therapeutics's return on sales has surged by 81% QoQ and by 71% YoY
The ROA has soared by 55% YoY and by 15% from the previous quarter
TGTX's ROIC is down by 18% QoQ

Dividends

What is TGTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TGTX.

Financial health

How did Tg Therapeutics financials performed over time
The quick ratio has decreased by 18% QoQ
TGTX's current ratio is down by 17% since the previous quarter
TGTX's debt is 91% lower than its equity
The debt to equity has soared by 100% YoY and by 13% from the previous quarter
The equity has declined by 14% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.